CD8A and neoplasm: The small‐molecule PRMT1 inhibitor DCPT1061 significantly increased the number and cytotoxic activity of tumor‐infiltrating CD8+ T cells, suppressed tumor growth, and sensitized treatment‐resistant melanomas to anti‐PD‐1 therapy [58].